<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684654</url>
  </required_header>
  <id_info>
    <org_study_id>IM039-004</org_study_id>
    <secondary_id>2019-003660-49</secondary_id>
    <secondary_id>U1111-1241-6583</secondary_id>
    <nct_id>NCT04684654</nct_id>
  </id_info>
  <brief_title>BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Dose Study on the Safety, Pharmacokinetics, and Exploratory Pharmacodynamics of Subcutaneous and Intravenous BMS-986325 Administration in Healthy Participants and Participants With Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug&#xD;
      effects of BMS-986325 in healthy participants and participants with primary Sjögren's&#xD;
      syndrome. The results will guide the future clinical development with BMS-986325.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2021</start_date>
  <completion_date type="Anticipated">April 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Body temperature</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Blood pressure</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval</measure>
    <time_frame>Up to 137 days</time_frame>
    <description>PR interval: The time from the onset of the P wave to the start of the QRS complex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS interval</measure>
    <time_frame>Up to 137 days</time_frame>
    <description>QRS interval: A combination of the Q wave, R wave and S wave, the &quot;QRS complex&quot; represents ventricular depolarization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval</measure>
    <time_frame>Up to 137 days</time_frame>
    <description>QT interval: Measured from the beginning of the QRS complex to the end of the T wave</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF interval</measure>
    <time_frame>Up to 137 days</time_frame>
    <description>QTcF interval: Corrected QT interval using Fridericia's formula (QTcF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in physical examination findings</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in inflammatory markers: C-reactive protein (CRP)</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in inflammatory markers: Interferon-gamma (IFN-γ)</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in inflammatory markers: Interleukin-1 beta (IL-1β)</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in inflammatory markers: Interleukin-6 (IL-6)</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in inflammatory markers: Interleukin-8 (IL-8)</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in inflammatory markers: Tumor necrosis factor alpha (TNFα)</measure>
    <time_frame>Up to 137 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Healthy Participants</condition>
  <condition>Primary Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Part A (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose (SAD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (SAD) Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Ascending Dose (MAD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (MAD) Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C (pSS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primary Sjögren's Syndrome (pSS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C (pSS) Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986325</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part A (SAD)</arm_group_label>
    <arm_group_label>Part B (MAD)</arm_group_label>
    <arm_group_label>Part C (pSS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for BMS-986325</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part A (SAD) Placebo</arm_group_label>
    <arm_group_label>Part B (MAD) Placebo</arm_group_label>
    <arm_group_label>Part C (pSS) Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI: 18.0 to 30.0 kg/m2, weight: ≥ 50 kg at screening&#xD;
&#xD;
          -  Must agree to follow specific methods of contraception, if applicable&#xD;
&#xD;
        Healthy Participants (Part A and Part B)&#xD;
&#xD;
          -  Healthy male and female participants as determined by no clinically significant&#xD;
             deviation from normal in medical history, physical examination (PE),&#xD;
             electrocardiograms (ECGs), and clinical laboratory determinations&#xD;
&#xD;
          -  Males and Females, ages 18, or local age of majority, to 50 years, inclusive at&#xD;
             screening&#xD;
&#xD;
        Participants with Sjögren's Syndrome (Part C)&#xD;
&#xD;
          -  Sjögren's syndrome in the absence of another immune-mediated disease or rheumatologic&#xD;
             condition based on the 2016 American College of Rheumatology-European League Against&#xD;
             Rheumatism (EULAR) Classification Criteria for primary Sjögren's syndrome (pSS)&#xD;
&#xD;
          -  Seropositive for anti-Sjögren's syndrome antigen A antibody&#xD;
&#xD;
          -  Males and females, ages 18, or local age of majority, to 65 years, inclusive at&#xD;
             screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Woman who are pregnant or breastfeeding&#xD;
&#xD;
          -  Inability to tolerate venipuncture and/or inadequate venous access&#xD;
&#xD;
        Healthy Participants (Part A and Part B)&#xD;
&#xD;
          -  Any significant acute or chronic medical illness&#xD;
&#xD;
          -  Any other significant medical, psychiatric, and/or social reason as determined by the&#xD;
             investigator&#xD;
&#xD;
        Participants with Sjögren's Syndrome (Part C)&#xD;
&#xD;
          -  Systemic immune-mediated disease other than pSS, such as rheumatoid arthritis (RA),&#xD;
             systemic lupus erythematosus (SLE), mixed connective tissue disease, or systemic&#xD;
             sclerosis, that can better explain the majority of the symptoms (i.e., secondary&#xD;
             Sjögren's syndrome)&#xD;
&#xD;
          -  Another immune-mediated disease or inflammatory condition that could interfere with&#xD;
             assessment of response of pSS to therapy (e.g., immunoglobulin G4 (IgG4)-related&#xD;
             disease, systemic sclerosis, inflammatory bowel disease, gout)&#xD;
&#xD;
          -  Any other medical condition associated with sicca syndrome (e.g., history of head and&#xD;
             neck radiation treatment, diabetes mellitus, sarcoidosis, chronic graft-versus host&#xD;
             disease), participants with sicca symptoms secondary to ongoing medication use based&#xD;
             on the investigator's assessment&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Sjögren's Syndrome</keyword>
  <keyword>Healthy participants</keyword>
  <keyword>BMS-986325</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

